StockData
VolitionRx Ltd logo

VolitionRx Ltd (VNRX) company profile

VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.19−0.01 (-5.56%)

Close on Nov 17, 2026Market cap $2.58MP/E –Yield –

About VolitionRx

In Vitro & In Vivo Diagnostic Substances, SIC 2835

VolitionRx Limited is a multi-national epigenetics company that develops blood-based tests to detect and monitor cancer and diseases associated with NETosis, such as sepsis. Its patented technologies, including Nu.Q and Capture-PCR/Capture-Seq, analyze circulating nucleosomes, transcription factors, and tumor-derived DNA in the blood to identify disease changes at early stages. The company's key product pillars encompass Nu.Q Vet for canine cancer screening and companion animal diagnostics, Nu.Q NETs for conditions linked to NETosis, Nu.Q Discover for nucleosome profiling in drug research, and Nu.Q Cancer for human oncology detection and monitoring. Volition serves veterinarians, pet owners, academic institutions, diagnostic providers, and pharmaceutical researchers.

The company operates a purpose-built 17,000 square foot laboratory and 10,000 square foot manufacturing facility in Gembloux, Belgium, alongside an innovation lab and offices in California, London, and Nevada. It employs 75 full-time equivalent staff members, and its canine cancer test is available across more than twenty countries. VolitionRx maintains its principal executive office in Henderson, Nevada.

Summary of the business section of VolitionRx's latest annual report, written by StockData.

Company profile

Company

Legal name
VolitionRx Ltd
Founded
1998
Headquarters
Henderson, NV
Address
1489 West Warm Springs Road, Suite 110 89014
Phone
1 (512) 774-8930
Employees
75, Dec 31, 2025
Industry
In Vitro & In Vivo Diagnostic Substances
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Sadler, Gibb & Associates, LLC, Draper, UT

Stock & identifiers

Ticker
VNRX
Exchange
NYSE
IPO date
Mar 2, 2012
Shares outstanding
14M, Aug 11, 2026
Public float
$72.91M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Apr 28, 2026
SEC CIK
93314
CUSIP
928661206
ISIN
US9286612067
FIGI
BBG000BQWFH2
Share class FIGI
BBG001SDZ7B2
EIN
91-1949078

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Cameron John ReynoldsPresident and CEO, Director4,157,341
Ann-Louise BatchelorGroup Chief Marketing Officer29,257
Gaetan MichelChief Operating Officer12,232
Gael ForterreChief Commercial Officer18,159
Nicholas PlummerGC - Volition Diagnostics407,267
Rodney Gerard RootsaertSecretary1,281,711
Jacob Vincent MicallefChief Scientific Officer665,292
Terig HughesChief Financial Officer684,970
Jasmine KwayCEO - Singapore Volition429,014
Salvatore Thomas ButeraCEO - Volition Veterinary375,203
Andrew RetterChief Medical Officer146,568
Guy Archibald InnesDirector3,317,974
Ethel RubinDirector252,948
Kim NguyenDirector336,372
Timothy I. StillDirector1,625,458
Phillip BarnesDirector67,368
Mickie HenshallDirector44,206
Alan ColmanDirector257,364

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Cameron Reynolds
President and Chief Executive Officer
$473.94K–$132.57K$31.72K$638.23K+15%
Dr. Gaetan Michel
Chief Operating Officer
$178.16K$23.30K–$238.16K$439.61K-3%
Dr. Salvatore Thomas Butera
Chief Executive Officer, Volition Vet
$296.08K–$77.79K$127.17K$501.04K+29%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 75 full-time equivalent (“FTE”) personnel compared to 85 as of December 31, 2024, reflecting the need to prioritize the cash utilization in our commercial and production activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?